BNTX Jan 2026 180.000 call
| Previous close | 1.7000 |
| Open | 1.7000 |
| Bid | 1.2000 |
| Ask | 2.1500 |
| Strike | 180.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.7000 - 1.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 342 |
Globe NewswireBioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via th
ZacksPfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
- Globe Newswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — P
